Pfizer Inc. invites investors and the general public to view and listen
to a webcast of a presentation by Pfizer’s Oncology leadership on
Sunday, April 6, 2014 at 1:30 p.m. Pacific Daylight Time, in connection
with the presentation of the final results of the PALOMA-1 Phase 2 trial
for palbociclib at the American Association for Cancer Research (AACR)
Annual Meeting 2014. There will be a Q&A session following the
presentation during the webcast.
This webcast is specifically tailored to the investment community. To
view and listen to the webcast, visit our website at www.pfizer.com
and click on the “Review of Palbociclib Phase 2 PALOMA-1 Results
at AACR Annual Meeting 2014” webcast link in the For Investors section
located on the lower right-hand corner of that page. Information on
accessing and pre-registering for the webcast will be available at www.pfizer.com
beginning today. Participants are advised to pre-register in advance of
the conference call.
You can also listen to the conference call by dialing either (866)
246-2545 in the United States and Canada or (706) 634-2365 outside of
the United States and Canada. The password is “AACR 2014”.
For medical and general questions about palbociclib, including
information about palbociclib clinical trials, please call
1-800-438-1985.
Visitors to www.pfizer.com
will be able to view and listen to an archived copy of the webcast of
the conference call.
About PALOMA-1
PALOMA-1 (also known as Study 1003 and TRIO-18) is a Phase 2 trial
designed to assess the progression-free survival (PFS) of palbociclib
(125 mg once daily for three out of four weeks in repeated cycles) in
combination with letrozole versus letrozole alone (2.5 mg once daily on
a continuous regimen) in post-menopausal women with ER+, HER2- advanced
breast cancer. PFS is comprised of time from randomization to time of
disease progression or death from any cause. PALOMA-1 was conducted in
collaboration with the Jonsson Cancer Center’s Revlon/UCLA Women’s
Cancer Research Program. PALOMA-1 is a multi-center trial with 101
global sites participating.
Copyright Business Wire 2014